BRAIN TUMOR SPORE GRANT

这个SPORE更新申请代表了来自UCSF综合癌症中心神经肿瘤学项目的跨学科研究团队的努力，将他们的知识和专业知识应用于脑肿瘤的转化研究。该申请的核心是五个转化研究项目，每个项目都由应用和基础研究人员组成的团队推动，每个项目都旨在创造对脑肿瘤治疗有用的新工具和疗法。项目一是一个非常成功的人口科学项目的延伸，旨在确定神经胶质瘤患者生存的重要因素。项目二是一个非常成功的成像项目的延伸，该项目旨在使用复杂的光谱技术来非侵入性地确定预测低级别胶质瘤生物学的因素。项目三以先前资助期开发的新型含药脂质纳米颗粒为基础，提出生产和测试新的治疗性纳米颗粒，这些纳米颗粒的分布可以通过对流增强输送来控制，并进行实时光谱监测。项目四提出了基于实验室和临床的研究，旨在澄清和利用在上一个资助期发现的Akt活化与对EGFR抑制剂厄洛替尼敏感性之间的负相关关系。项目五是由前一个资助期的两个发展研究项目融合而来，提出了基于实验室和临床的研究，旨在调查和利用PTEN/Akt/mTOR通路在神经胶质瘤疫苗治疗反应中的作用。申请还要求继续支持非常成功的职业发展和发展研究计划，以及四个核心（现有的组织和管理核心以及新的动物和生物统计学/临床核心），这些核心将支持工作的各个方面。每个项目都借鉴了研究人员在脑肿瘤研究方面的丰富经验，以及加州大学旧金山分校神经外科和加州大学旧金山分校脑肿瘤研究中心的脑肿瘤转化研究的悠久历史。这些项目将通过与加州大学旧金山分校综合癌症中心和加州大学旧金山分校乳腺和前列腺孢子的科学家合作而得到进一步加强。最后，作为美国领先的脑肿瘤临床试验中心，UCSF神经肿瘤学项目的基础设施已经到位，可以快速将重要的科学发现转化为临床研究。

This SPORE renewal application represents the efforts of interdisciplinary teams of investigators from the Neuro-Oncology Program of the UCSF Comprehensive Cancer Center to apply their knowledge and expertise to translational research focused on brain tumors. The heart of the application is five translational research projects, each driven by teams of applied and basic investigators, and each intended to create novel tools and therapies useful in the treatment of brain tumors. Project One is an extension of a highly successful population science project that intends to define factors important in glioma patient survival. Project Two is an extension of a highly successful imaging project that intends to use sophisticated spectroscopic techniques to non-invasively define factors that predict low-grade glioma biology. Project Three builds on novel drug-containing lipidic nanoparticles developed in the previous funding period, and proposes to generate and test new therapeutic nanoparticles whose distribution can be controlled by convection-enhanced delivery and monitored in real time spectroscopically. Project Four proposes lab based and clinical studies intended to clarify and exploit the negative association discovered in the previous funding period between Akt activation and sensitivity to the EGFR inhibitor erlotinib. Project Five, which evolved from the convergence of two Developmental Research Projects in the previous funding period, proposes lab-based and clinical studies intended to investigate and exploit the role the PTEN/Akt/mTOR pathway plays in response to glioma vaccine therapy. The application also requests continued support for highly successful Career Development and Developmental Research Programs, and for four Cores (the existing Tissue and Administrative Cores and the new Animal and Biostatistics/Clinical Core) that will support all aspects of the work. Each project draws on the extensive experience of the investigators in brain tumor research, and on the long history of translational brain tumor research in the UCSF Department of Neurological Surgery and UCSF Brain Tumor Research Center. The projects will be additionally strengthened by collaborations with scientists in the UCSF Comprehensive Cancer Center and in the UCSF Breast and Prostate SPOREs. Finally, as a leading center of brain tumor clinical trials in America, an infrastructure is in place in the UCSF Neuro-Oncology Program to allow rapid clinical translation of important scientific discoveries. The Principal Investigator of the UCSF Brain Tumor SPORE is Mitchel Berger, MD, a nationally recognized leader in neurosurgery and translational brain tumor research. The clinical co-PI of this application is Michael Prados, MD, the PI of the North American Brain Tumor Consortium and a recognized leader in the development and implementation of clinical trials in brain tumors. The basic science co-PI of this application is Russell Pieper, PhD, the Basic Science Director of the UCSF Neuro-Oncology Program and the UCSF Brain Tumor Research Center and a recognized leader in the study of cell signaling in gliomas. The combined administrative, clinical, and lab-based experience of the leadership team, along with the strong interdisciplinary research teams and the strong research climate at UCSF suggest that the work proposed will lead to significant progress in the treatment of brain tumors.